Analogue peptides for the immunotherapy of human acute myeloid leukemia
Name:
2015 Hofmann et al peptide ...
Size:
307.1Kb
Format:
PDF
Description:
Accepted manuscript. The final ...
Affiliation
University of BedfordshireIssue Date
2015-10-05Subjects
analogue peptidesadult acute myeloid leukemia
clinical trials
PASD1
heteroclitic peptides
NPM1
peptides
immunotherapy
C550 Immunology
Metadata
Show full item recordAbstract
The use of peptide vaccines, enhanced by adjuvants, has shown some efficacy in clinical trials. However, responses are often short-lived and rarely induce notable memory responses. The reason is that self-antigens have already been presented to the immune system as the tumor develops, leading to tolerance or some degree of host tumor cell destruction. To try to break tolerance against self-antigens, one of the methods employed has been to modify peptides at the anchor residues to enhance their ability to bind major histocompatibility complex molecules, extending their exposure to the T-cell receptor. These modified or analogue peptides have been investigated as stimulators of the immune system in patients with different cancers with variable but sometimes notable success. In this review we describe the background and recent developments in the use of analogue peptides for the immunotherapy of acute myeloid leukemia describing knowledge useful for the application of analogue peptide treatments for other malignancies.Citation
Hofmann, S., Mead, A., Malinovskis, A., Hardwick, N.R., Guinn B. (2015) 'Analogue peptides for the immunotherapy of human acute myeloid leukemia'. Cancer Immunology, Immunotherapy 64 (11):1357-67Publisher
SpringerJournal
Cancer Immunology, ImmunotherapyAdditional Links
http://link.springer.com/10.1007/s00262-015-1762-9Type
ArticleLanguage
enDescription
Accepted manuscript. The final publication is available at: http://link.springer.com/article/10.1007%2Fs00262-015-1762-9ISSN
0340-70041432-0851
Sponsors
Dr Susanne Hofmann received funding from the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG) and Drs Nicola Hardwick and Barbara Guinn from Leukaemia and Lymphoma Research.ae974a485f413a2113503eed53cd6c53
10.1007/s00262-015-1762-9
Scopus Count
Collections
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Archived with thanks to Cancer Immunology, Immunotherapy